Clinical Trials
12 trialsNCT03580655 2026-04-24
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2 Completed
NCT02571036 2023-12-13
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Phase 1 Completed
NCT02561988 2023-03-17
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Blueprint Medicines Corporation
Phase 1 Completed
NCT04695431 2022-01-10
Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
Blueprint Medicines Corporation
Completed
NCT00109707 2021-06-29
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
Novartis
Phase 1/2 Completed
NCT02620254 2021-02-04
Mast Cell Connect: A Registry for Patients With Mastocytosis
Blueprint Medicines Corporation
Completed
NCT00814073 2019-12-03
AB06006
AB Science
Phase 3 Completed
NCT02808793 2019-03-13
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
Allakos Inc.
Phase 1 Completed
NCT00782067 2018-11-15
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
Novartis
Phase 2 Completed
NCT00171912 2017-02-23
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Novartis
Phase 2 Completed
NCT02380222 2017-01-10
Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
Adelphi Values LLC
Completed
NCT02478957 2016-09-29
Treatment of Indolent Systemic Mastocytosis With PA101
Patara Pharma
Phase 2 Completed